Tenax Therapeutics Inc

Company Profile

Tenax Therapeutics Inc had its IPO on 1997-01-02 under the ticker symbol TENX.

The company operates in the Healthcare sector and Biotechnology industry. Tenax Therapeutics Inc has a staff strength of 7 employees.

Stock update

Shares of Tenax Therapeutics Inc opened at $0.35 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $0.32 - $0.36, and closed at $0.36.

This is a -1.39% slip from the previous day's closing price.

A total volume of 1,170,000 shares were traded at the close of the day’s session.

In the last one week, shares of Tenax Therapeutics Inc have increased by +5.97%.

Tenax Therapeutics Inc's Key Ratios

Tenax Therapeutics Inc has a market cap of $7.73 million, indicating a price to book ratio of 1.5883 and a price to sales ratio of 0.

In the last 12-months Tenax Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-9868784. The EBITDA ratio measures Tenax Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Tenax Therapeutics Inc’s operating margin was 0% while its return on assets stood at -64.93% with a return of equity of -122.55%.

In Q1, Tenax Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Tenax Therapeutics Inc’s PE and PEG Ratio

Forward PE

0.5404

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-5.46 per share while it has a forward price to earnings multiple of 0.5404 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tenax Therapeutics Inc’s profitability.

Tenax Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.2316. Its price to sales ratio in the trailing 12-months stood at 0.

Tenax Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$15.27 million

Total Liabilities

$983861.00

Operating Cash Flow

$0

Capital Expenditure

$1241

Dividend Payout Ratio

0%

Tenax Therapeutics Inc ended 2023 with $15.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.27 million while shareholder equity stood at $14.28 million.

Tenax Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $983861.00 in other current liabilities, 2178.00 in common stock, $-290948840.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.41 million and cash and short-term investments were $14.41 million. The company’s total short-term debt was $513,906 while long-term debt stood at $0.

Tenax Therapeutics Inc’s total current assets stands at $15.26 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $172034.00 and inventory worth $0.

In 2023, Tenax Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1241.

Comparatively, Tenax Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.36

52-Week High

$13.8

52-Week Low

$0.282

Analyst Target Price

$5.5

Tenax Therapeutics Inc stock is currently trading at $0.36 per share. It touched a 52-week high of $13.8 and a 52-week low of $13.8. Analysts tracking the stock have a 12-month average target price of $5.5.

Its 50-day moving average was $0.36 and 200-day moving average was $2.04 The short ratio stood at 0.28 indicating a short percent outstanding of 0%.

Around 248% of the company’s stock are held by insiders while 189% are held by institutions.